4 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 11 Phase 2, 6 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Recruiting 3, Terminated 3, Active not recruiting 1 |
| Phase 3 | 6 | Recruiting 3, Terminated 2, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Netherton Syndrome: new trials by email Literature Review of Netherton Syndrome trials Research Report on Netherton Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Secukinumab, Placebo - Ichthyosis, Autosomal Recessive Congenital Ichthyosis | Phase 2 | Completed | Northwestern University | 20 | 2016-12-01 | 2021-08-25 |
| Clinical Trial Using Humira in Netherton Syndrome Adalimumab - Netherton Syndrome | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2014-01-27 | 2026-04-08 |
| Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome Pimecrolimus 1% Cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 3 | 2005-09-01 | 2019-08-14 |
Hyperkeratosis, Epidermolytic (1) · Ichthyosiform Erythroderma, Congenital (1) · Ichthyosis (1) · Ichthyosis, Lamellar (1)
Abnormalities, Multiple (11) · Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Infant, Newborn, Diseases (11) · Keratosis (11) · Skin Abnormalities (11) · Skin Diseases (11) · Skin Diseases, Genetic (11) · Skin and Connective Tissue Diseases (11) · Ichthyosiform Erythroderma, Congenital (10) · Ichthyosis (10)
Adalimumab (1) · Injections (1) · WAS protein, human (1) · pimecrolimus (1) · secukinumab (1) · spesolimab (1)
Quoin Pharmaceuticals (4) · Assistance Publique - Hôpitaux de Paris (1) · Boehringer Ingelheim (1) · Children's Hospital of Philadelphia (1) · Daiichi Sankyo (1) · Northwestern University (1) · Sixera Pharma (1) · University Hospital, Toulouse (1)
United States (7) · France (5) · Germany (2) · United Kingdom (2) · Australia (1) · Austria (1) · Bulgaria (1) · China (1) · Israel (1) · Italy (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Portugal (1) · Sweden (1)
Tony Andrasfay (2) · Albert C Yan, MD (1) · Amy Paller, MD (1) · Christine Bodemer, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Maarten de Chateau, MD PhD (1)